Literature DB >> 18793167

The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice.

Ruth Brownlie1, Rachel M Mayers, Jackie A Pierce, Anna E Marley, David M Smith.   

Abstract

GPR40 (G-protein-coupled receptor 40) has been shown to be a physiologically relevant receptor for long-chain fatty acids. It is a family A G-protein-coupled receptor highly expressed in the beta-cell where it increases insulin secretion by signalling via Gq and phospholipase C. Fatty acids are well known to mediate both acute stimulatory effects and chronic detrimental effects on the beta-cell. GPR40-transgenic and GPR40-/- animals have been important tools in studies of the metabolic effects of GPR40. In the present article, we review the literature on transgenic GPR40 models and present some of our own studies on the effects of a high-fat diet on the metabolic phenotype of GPR40-/- mice. GPR40 ligands represent interesting novel therapies for Type 2 diabetes but it is presently unclear whether agonists or antagonists represent the best therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793167     DOI: 10.1042/BST0360950

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  13 in total

Review 1.  The year in G protein-coupled receptor research.

Authors:  Robert P Millar; Claire L Newton
Journal:  Mol Endocrinol       Date:  2009-12-17

2.  G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1.

Authors:  M Ferdaoussi; V Bergeron; B Zarrouki; J Kolic; J Cantley; J Fielitz; E N Olson; M Prentki; T Biden; P E MacDonald; V Poitout
Journal:  Diabetologia       Date:  2012-07-22       Impact factor: 10.122

3.  Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.

Authors:  Venkat Vangaveti; Venkatesh Shashidhar; Ghassan Jarrod; Bernhard T Baune; R Lee Kennedy
Journal:  Ther Adv Endocrinol Metab       Date:  2010-08       Impact factor: 3.565

4.  Fatty acid binding receptors in intestinal physiology and pathophysiology.

Authors:  Elke Kaemmerer; Patrick Plum; Christina Klaus; Ralf Weiskirchen; Christian Liedtke; Maximilian Adolf; Angela Schippers; Norbert Wagner; Andrea Reinartz; Nikolaus Gassler
Journal:  World J Gastrointest Pathophysiol       Date:  2010-12-15

5.  Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.

Authors:  Elisabeth Christiansen; Maria E Due-Hansen; Christian Urban; Nicole Merten; Michael Pfleiderer; Kasper K Karlsen; Sanne S Rasmussen; Mette Steensgaard; Alexandra Hamacher; Johannes Schmidt; Christel Drewke; Rasmus Koefoed Petersen; Karsten Kristiansen; Susanne Ullrich; Evi Kostenis; Matthias U Kassack; Trond Ulven
Journal:  ACS Med Chem Lett       Date:  2010-07-02       Impact factor: 4.345

Review 6.  Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3.

Authors:  Graeme Milligan; Leigh A Stoddart; Nicola J Smith
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

7.  The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.

Authors:  Nicola J Smith; Leigh A Stoddart; Nicola M Devine; Laura Jenkins; Graeme Milligan
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

Review 8.  Lipid receptors and islet function: therapeutic implications?

Authors:  M A Kebede; T Alquier; M G Latour; V Poitout
Journal:  Diabetes Obes Metab       Date:  2009-11       Impact factor: 6.577

Review 9.  Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.

Authors:  Bo Ahrén
Journal:  Nat Rev Drug Discov       Date:  2009-04-14       Impact factor: 84.694

10.  TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes.

Authors:  Meera Shah; Ron T Varghese; John M Miles; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Kent R Bailey; Robert A Rizza; Adrian Vella
Journal:  Diabetes       Date:  2015-11-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.